Preclinical evaluation of novel radionuclide therapies in different cancer models
Medicine is not yet able to cure the majority of ovarian cancer patients. In this PhD, we will address new therapeutic avenues, based on radionuclides. Radium-224 labeled microparticles and microparticles and antibodies labeled with lead-212 will be studied in an ovarian cancer mouse model. Because we expect immune modulatory effects of both products, combinatorial treatments, including chemotherapy and immunotherapy, will be tested in a second phase. In a third phase, we will explore if beneficial effects of the products (or their combinations) can be generalized to different cancers.